|
News
|
Israel | Vegetable Health
Lavie Bio announces positive results for LAV311 and LAV312 in its biofungicide program Positive results were obtained in a series of vineyard trials for bunch rot diseases conducted in Europe and the United States. 10/29/2020
 Example of treatment with LAV312 against Botrytis cinerea in grapevines.
Lavie Bio Ltd. (Lavie Bio), a leading agricultural biologics company focused on improving food quality, sustainability and agricultural productivity through the introduction of microbiome-based products, and a subsidiary of Evogene Ltd ., today announced positive test results for two of its leading bio-fungicide product candidates. The successful results of LAV311 and LAV312, targeting bunch rot diseases, mark the advancement of these candidates to "Stage of development 2". These vineyard trials, conducted at target locations in Europe and the US, resulted in significantly better efficacy and consistency than existing comparable commercial biological benchmarks, and competitive with commercial chemical benchmarks, both tested as part of these trials. The positive results will support Lavie Bio's current plan to launch its first bio-fungicidal product to control bunch rot for use on fruits and vegetables in 2024. Damages from crop diseases are increasing, and current efforts rely heavily on chemical crop protection, with fungicidal chemicals accounting for $ 18.7 billion in annual expenditures in 2019. As a result of the With increasing resistance to disease from existing chemicals and the demand for more sustainability practices, there is a recognized and rapidly growing need for new and effective solutions, with agrobiology an important tool to address this challenge. Bunch rots are devastating diseases and the estimated annual expenditure on crop protection with existing chemical solutions is $ 100 million. New and effective biologics can be integrated into the farmer's existing IPM (Integrated Pest Management) practices, thus promoting productive and sustainable practices, while reducing the emergence of pest resistance in existing crop protection solutions . Lavie Bio's bio-fungicide program addresses cluster rots currently concentrated on vines with the goal of spreading to other crops. The main candidate products, LAV311 and LAV312, were developed based on the use of Lavie Bio's BDD (Biology Driven Design) platform, resulting in an optimized combination of live microbial strains, formulation and fermentation technologies. Positive results were achieved in repeated vineyard trials during the years 2019 and 2020, representing a variety of conditions, such as grape types, agricultural practices, and climates. These trials showed that vineyards treated with each of LAV311 and LAV312 demonstrated a 60-70% reduction in crop damage due to bunch rot compared to the control. Looking ahead, Lavie Bio's activities in "Development Stage 2" are expected to focus on further advancement of LAV311 and LAV312 formulation and fermentation, as well as broadening the spectrum of target crops and diseases. Mr. Ido Dor, CEO of Lavie Bio, stated: “The potential to introduce a solution that could generate new value for both the farmer and the consumer by improving the productivity, sustainability and quality of the products we consume, it's exciting and it motivates us at Lavie Bio. It is fantastic to see how Lavie Bio's multidisciplinary team, powered by our proprietary BDD platform, makes a difference and enables the introduction of new agrobiological solutions that are 'better by nature'. " Mr. Ofer Haviv, President of Lavie Bio and President and CEO of Evogene, stated, “The progress made in Lavie Bio's bio-fungicide program is another testament to the value and impressive progress that can be made using biology. computational. This achievement represents another product moving toward commercialization that benefited from the technology platform of our subsidiary, BDD, powered by Evogene's 'MicroBoost AI' engine. " Lavie Bio Ltd. Lavie Bio, a subsidiary of Evogene, aims to improve food quality, sustainability and agricultural productivity through the introduction of microbiome-based agrobiological products. Lavie Bio uses a proprietary computational predictive platform, which harnesses the power of big data and advanced computing, for the discovery, optimization and development of biostimulants and biopesticide products. Corteva Inc. owns approximately 28% of Lavie Bio. Evogene Ltd. Evogene is a leading computational biology company focused on revolutionizing product discovery and development in multiple life science-based industries, including human health and agriculture, by using our Computational Predictive Biology (CPB) platform from wide application. The CPB platform, which incorporates a deep understanding of biology harnessed through the power of Big Data and Artificial Intelligence, has been designed to computationally discover and uniquely guide the development of life science products based on microbes, small molecules and genetic elements. Using the CPB platform, Evogene and its subsidiaries are now advancing product lines for human microbiome-based therapies through Biomica Ltd., medical cannabis through Canonic Ltd., agricultural biologics through Lavie Bio Ltd., products. agricultural chemicals through AgPlenus Ltd., and agricultural solutions for castor oil production through Casterra Ag Ltd.
Sign up to our newsletter
|
|||||||||
© Copyright Infoagro Systems, S.L.
